KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort

Author:

Habashy Paul12,Lea Vivienne13,Wilkinson Kate4,Wang Bin15,Wu Xiao-Juan3,Roberts Tara Laurine256ORCID,Ng Weng2456,Rutland Tristan123,Po Joseph William57,Becker Therese256ORCID,Descallar Joseph56,Lee Mark8,Mackenzie Scott29,Gupta Ruta10,Cooper Wendy11011,Lim Stephanie2512,Chua Wei245,Lee Cheok Soon1235610

Affiliation:

1. Discipline of Pathology, School of Medicine, Western Sydney University, Sydney, NSW 2560, Australia

2. Liverpool Clinical School, Western Sydney University, Sydney, NSW 2170, Australia

3. Department of Anatomical Pathology, Liverpool Hospital, Sydney, NSW 2170, Australia

4. Department of Medical Oncology, Liverpool Hospital, Sydney, NSW 2170, Australia

5. Ingham Institute for Applied Medical Research, Liverpool Hospital, Sydney, NSW 2170, Australia

6. South Western Sydney Clinical School, University of New South Wales, Sydney, NSW 2170, Australia

7. Surgical Innovations Unit, Department of Surgery, Westmead Hospital, Sydney, NSW 2140, Australia

8. Department of Radiation Oncology, Liverpool Hospital, Sydney, NSW 2170, Australia

9. Department of Surgery, Liverpool Hospital, Sydney, NSW 2170, Australia

10. Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia

11. Sydney Medical School, University of Sydney, Sydney, NSW 2050, Australia

12. Department of Medical Oncology, Campbelltown Hospital, Sydney, NSW 2560, Australia

Abstract

KRAS and BRAF mutation rates in colorectal cancer (CRC) reported from various mono-ethnic studies vary amongst different ethnic groups. However, these differences in mutation rates may not be statistically significant or may be due to differences in environmental and/or laboratory factors across countries rather than racial genetic differences. Here, we compare the KRAS/BRAF mutation rates and survival outcomes in CRC between ethnic groups at a single institution. We also investigate the contributions of genetic, environmental, and laboratory factors to the variations in KRAS/BRAF mutation rates reported from different countries. Clinicopathological data from 453 ethnically diverse patients with CRC were retrospectively analyzed at Liverpool Hospital, NSW Australia (2014–2016). KRAS/BRAF mutations were detected using real-time PCR (Therascreen kits from Qiagen). Mismatch repair (MMR) status was determined using immunohistochemical staining. Four ethnic groups were analyzed: Caucasian, Middle Eastern, Asian, and South American. Overall survival data were available for 406 patients. There was no significant difference in KRAS mutation rates between Caucasians (41.1%), Middle Easterners (47.9%), Asians (44.8%), and South Americans (25%) (p = 0.34). BRAF mutation rates differed significantly between races (p = 0.025), with Caucasians having the highest rates (13.5%) and Middle Easterners the lowest (0%). A secondary analysis in which Caucasians were divided into three subgroups showed that ethnic grouping correlated significantly with KRAS mutation rate (p = 0.009), with central and eastern Europeans having the highest rates (58.3%). There were no significant differences in overall survival (OS) or disease-free survival (DFS) between the four races. The similarity in KRAS mutation rates across races raises the possibility that the differences in KRAS mutation rates reported from various countries may either not be statistically significant or may be due to environmental and/or laboratory factors rather than underlying racial genetic differences. In contrast, we verified that BRAF mutation rates differ significantly between races, suggesting racial genetic differences may be responsible for the discrepant BRAF mutation rates reported from different countries.

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference66 articles.

1. Worldwide Cancer Data [Internet] (2021, August 03). London: World Cancer Research Fund International. Available online: https://www.wcrf.org/dietandcancer/worldwide-cancer-data/.

2. KRAS mutation testing in metastatic colorectal cancer;Tan;World J. Gastroenterol.,2012

3. RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data;Kafatos;Biomark. Med.,2017

4. Molecular pathways in colorectal cancer;Biankin;J. Gastroenterol. Hepatol.,2012

5. László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., and Vas, V. (2021). Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology. Cells, 10.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3